optic neuritis: Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain.The conditionmay cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis , drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.
Retrobulbar neuritis in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
H7_RETROBULBNEURINOTH
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
149 |
4. Check minimum number of eventsNone |
149 |
5. Include endpointsNone |
149 |
6. Filter based on genotype QC (FinnGen only) |
131 |
Control definitions (FinnGen only)
- Control exclude
- H7_OPTNERVE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Retrobulbar neuritis in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Disorders of optic nerve and visual pathways
- Diseases of the eye and adnexa
- Any operation in hilmo
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 604 | 436 | 164 |
| Only index persons | 579 | 422 | 157 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 41.59 | 42.05 | 40.49 |
| Only index persons | 41.30 | 41.71 | 40.20 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 131 | 104 | 27 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.01 |
| Median age at first event (years) | 40.13 | 39.68 | 41.88 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 140
- Matched controls
- 1400
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G35
ICD-10 Finland
Multiple sclerosis
1617.7
153.6
123
6
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
141.9
111
*
109
Kela drug reimbursment
Multiple sclerosis
995.8
132.0
110
5
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
787.7
122.4
104
5
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
542.2
105.7
93
5
H46
ICD-10 Finland
Optic neuritis
+∞
103.3
86
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
21.3
76.5
78
78
XCK00
NOMESCO Finland
Perimetry
32.5
72.5
52
25
L03AB07
ATC
interferon beta-1a; parenteral
565.0
69.0
63
*
N86
ICPC
Multiple sclerosis
503.3
64.0
59
*
L03AX13
ATC
glatiramer acetate; parenteral
361.0
50.6
48
*
TAB00
NOMESCO Finland
Lumbar puncture
16.4
49.8
50
46
164
Kela drug reimbursment
Fingolimod
647.2
48.4
45
*
353
Kela drug reimbursment
Cladribine and fingolimod
585.4
44.9
42
*
ZX120
NOMESCO Finland
Intravenous
12.4
41.4
50
60
L04AA27
ATC
[U] fingolimod
+∞
39.5
36
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
12.6
36.7
42
46
L03AB08
ATC
interferon beta-1b; parenteral
431.3
34.5
33
*
N04BB01
ATC
amantadine; oral
115.4
33.5
35
*
XKD00
NOMESCO Finland
Uroflowmetry
12.3
33.4
38
41
2AB04, ,
NOMESCO Finland
213.8
33.3
33
*
L04AX07
ATC
dimethyl fumarate; oral
142.6
32.2
33
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
38.0
31.0
39
14
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
12.5
30.7
34
35
XA800
NOMESCO Finland
Neuropsychological investigation
11.6
29.9
35
39
Z01.0
ICD-10 Finland
Examination of eyes and vision
7.0
27.7
59
132
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
75.6
27.2
30
5
L04AA31
ATC
[U] teriflunomide
+∞
25.8
24
*
H02AB04
ATC
methylprednisolone; systemic
6.7
24.9
52
113
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
55.2
23.3
27
6
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
22.5
21
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
31.4
21.4
28
11
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.5
21.3
36
62
M03BX01
ATC
baclofen; systemic
28.7
21.0
28
12
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
22.1
20.7
30
17
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
20.3
19
*
G04BD12
ATC
mirabegron; oral
7.4
19.2
32
54
XCD10
NOMESCO Finland
Electrophysiological examination of eye
26.2
19.0
26
12
Z3226
NOMESCO Finland
Physiotherapist
5.2
18.8
53
147
Z3231
NOMESCO Finland
Registered nurse
4.8
18.7
67
226
4AA23, ,
NOMESCO Finland
+∞
18.1
17
*
N07XX09
ATC
[U] dimethyl fumarate
72.6
17.2
19
*
G04BD04
ATC
oxybutynin; oral, transdermal
8.1
15.8
23
33
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
28.9
15.2
20
8
H48.1*A69.2
ICD-10 Finland
Retrobulbar neuritis in Lyme disease
+∞
14.8
14
*
Z3229
NOMESCO Finland
Other healthcare associate professional
6.6
14.4
26
47
G04BD09
ATC
trospium; oral
34.1
14.3
18
6
R4110
NOMESCO Finland
Physiotherapy
3.9
14.1
64
247
L04AE01
ATC
fingolimod; oral
+∞
13.8
13
*
XF400
NOMESCO Finland
ECG with 12 standard connections
5.0
13.3
34
85
Z2446
NOMESCO Finland
Social worker
6.5
12.9
23
41
Z2445
NOMESCO Finland
Psychologist
7.1
12.9
21
34
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
22.7
12.8
18
9
N05CF01
ATC
zopiclone; oral
3.7
12.8
62
248
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.6
12.7
27
57
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
51.4
12.1
14
*
N03AE01
ATC
clonazepam; systemic
9.4
11.7
24
30
H47.2
ICD-10 Finland
Optic atrophy
+∞
11.6
11
*
R35
ICD-10 Finland
Polyuria
6.2
11.3
21
39
UKC02
NOMESCO Finland
Cystoscopy
4.8
10.8
28
70
TPH04
NOMESCO Finland
Cathetrisation of vein
3.6
10.8
46
166
TKC20
NOMESCO Finland
Catheterisation of bladder
9.5
10.8
22
27
R1250
NOMESCO Finland
Evaluation of functional capability
15.9
10.8
17
12
Z2221
NOMESCO Finland
Medical doctor
3.3
10.8
64
285
ZXD10
NOMESCO Finland
Scheduled procedure
3.2
10.6
69
323
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
10.5
10
*
L04AG12
ATC
ofatumumab; parenteral
+∞
10.5
10
*
N06BA07
ATC
modafinil; oral
35.5
10.5
13
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
20.8
10.5
15
8
R4150
NOMESCO Finland
Neuropsychological rehabilitation
18.5
10.1
15
9
N39.4
ICD-10 Finland
Other specified urinary incontinence
5.1
10.0
23
52
R2110
NOMESCO Finland
Giving the first information
5.1
9.7
22
49
ZXA10
NOMESCO Finland
Bilateral
3.7
9.6
37
124
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.0
9.6
32
97
A28
ICPC
Limited function/disability NOS
4.3
9.6
28
77
J01EA01
ATC
trimethoprim; systemic
3.1
9.5
56
245
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
+∞
9.5
9
*
L04AX01
ATC
azathioprine; systemic
8.5
9.3
20
27
R4120
NOMESCO Finland
Occupational therapy
4.9
9.2
22
51
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.1
9.2
29
84
G04BD08
ATC
solifenacin; oral
8.1
9.1
20
28
R20.2
ICD-10 Finland
Paraesthesia of skin
4.2
9.1
27
75
L04AA40
ATC
cladribine; oral
95.6
8.5
9
*
A02BC02
ATC
pantoprazole; systemic
3.3
8.5
109
718
N99
ICPC
Neurological disease other
35.6
8.2
10
*
H53.1
ICD-10 Finland
Subjective visual disturbances
4.2
8.1
24
66
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.8
8.0
19
44
N03AX12
ATC
[U] gabapentin; oral
3.2
7.8
37
141
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
26.7
7.7
10
*
R5110, ,
SPAT
4.6
7.5
19
46
N03AX16
ATC
[U] pregabalin
3.0
7.5
43
182
N30.0
ICD-10 Finland
Acute cystitis
3.0
7.5
40
163
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
+∞
7.3
7
*
L04AK02
ATC
teriflunomide; oral
+∞
7.3
7
*
C10AC01
ATC
colestyramine; oral
9.6
7.2
14
16
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
31.8
7.2
9
*
TKC22
NOMESCO Finland
Catheterisation instruction
31.8
7.2
9
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
7.1
61
317
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.2
7.1
20
53
N29
ICPC
Neurological sympt/complt other
14.8
7.0
11
8
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
10.1
7.0
13
14
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
42.2
6.8
8
*
R42
ICD-10 Finland
Dizziness and giddiness
2.9
6.8
38
158
H02AB07
ATC
prednisone; oral
3.4
6.7
27
92
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
13.1
6.7
11
9
L28
ICPC
Limited function/disability (L)
3.1
6.6
31
116
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
15.2
6.5
10
7
ZXE00
NOMESCO Finland
One hour or less
2.5
6.5
70
402
G04BD07
ATC
tolterodine; oral
8.8
6.5
13
16
U07
ICPC
Urine symptom/complaint other
3.9
6.4
20
57
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.1
6.4
31
118
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
10.0
6.4
12
13
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.3
6.4
16
28
SPAT1229
SPAT
Assessment of need for aid
6.9
6.4
15
24
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.2
6.3
18
48
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
6.3
6
*
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
+∞
6.3
6
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.4
6.2
25
85
H53.9
ICD-10 Finland
Visual disturbance, unspecified
6.1
6.2
16
29
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
13.3
6.2
10
8
N28
ICPC
Limited function/disability (N)
13.3
6.2
10
8
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.4
6.0
24
81
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
6.9
6.0
14
22
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
52
22
37.01
76.14
1.2
1.1
—
—
—
0
0
76
174
8.37
36.15
7.3
2.4
1.09
0.85
e6/l
0.28
46
84
70
157
7.92
33.60
7.8
2.5
5.31
4.00
e6/l
0.28
39
67
37
52
9.31
26.42
1.7
1.3
—
—
—
0
0
88
296
6.31
26.35
10.5
2.5
0.19
0.33
e6/l
0.58
73
200
23
0
+∞
24.71
1.3
0.0
—
—
—
0
0
28
37
9.21
20.76
1.1
1.3
7.50
20.36
e6/l
0.32
16
28
27
37
8.80
19.39
1.1
1.4
14.07
171.40
e6/l
0.51
15
30
128
727
9.87
18.17
23.5
10.1
3.48
3.97
e9/l
2.84
118
639
23
9
30.24
17.56
1.0
1.0
—
—
—
0
0
21
16
15.21
12.93
1.0
1.1
—
—
—
0
0
111
647
4.45
12.78
7.2
3.5
0.00
0.00
estimate
—
10
137
21
17
14.30
12.61
1.0
1.2
—
—
—
0
0
111
655
4.35
12.36
7.3
3.5
0.00
0.00
estimate
-0.00
11
137
20
16
14.36
12.07
1.0
1.2
—
—
—
0
0
110
657
4.15
11.75
7.2
3.6
0.00
0.00
estimate
—
10
130
14
10
15.38
8.90
1.1
1.0
1908.43
1737.80
miu/ml
—
14
10
31
112
3.27
7.04
1.6
1.8
—
—
—
0
0
29
108
3.13
6.23
1.6
1.8
—
—
—
0
0
10
8
13.33
6.18
1.5
1.6
—
—
—
0
0
17
48
3.89
5.52
1.5
1.7
—
—
—
0
0
10
12
8.87
5.15
1.0
1.3
—
—
—
0
0
27
114
2.70
4.58
3.5
2.5
28.38
29.02
u/l
0.05
21
95
12
23
5.60
4.57
3.1
3.0
2.17
1.31
index
—
6
13
10
15
7.09
4.55
1.3
1.0
—
—
—
0
0
11
21
5.59
4.24
1.3
1.3
—
—
—
0
0
11
21
5.59
4.24
1.3
1.3
—
—
—
0
0
33
163
2.34
4.03
1.8
2.0
—
—
—
0
0
129
1089
3.35
3.97
36.0
15.4
13.44
13.39
%
0.15
129
1082
140
1307
+∞
3.62
25.3
10.6
25.54
25.62
u/l
0.02
140
1287
6
6
10.37
3.53
1.0
1.7
—
—
—
0
0
133
1182
3.50
3.44
22.3
11.4
97.85
91.05
ml/min/173m2
4.19
127
1084
14
48
3.13
3.41
8.6
9.2
94.59
94.74
%
0.04
14
48
73
511
1.90
3.41
11.3
6.3
1.21
1.22
mmol/l
0.64
65
440
13
44
3.15
3.23
4.0
1.6
106.00
99.57
%
0.39
13
44
9
22
4.30
2.93
4.4
1.1
0.00
0.00
g/l
—
9
22
13
47
2.95
2.90
22.7
2.0
24.46
24.59
mmol/l
0.06
13
47
66
466
1.79
2.85
11.8
5.7
1.21
1.22
mmol/l
0.85
66
437
12
39
3.27
2.85
4.3
2.1
149.67
164.82
%
0.32
12
39
67
480
1.76
2.72
2.2
2.0
92.66
94.56
pmol/l
0.15
35
257
27
145
2.07
2.65
3.3
2.6
5.95
5.10
umol/l
0.23
22
126
31
194
1.77
1.93
3.2
2.6
57.33
366.12
ng/l
0.76
18
105
9
34
2.76
1.90
1.0
1.3
—
—
—
0
0
20
110
1.95
1.84
21.5
6.0
105.10
105.06
mmol/l
0.01
20
110
131
1212
2.26
1.79
23.9
12.6
139.60
139.77
mmol/l
0.30
131
1187
42
292
1.63
1.78
2.5
1.8
0.51
1.06
mg/l
1.47
32
219
15
78
2.03
1.61
20.1
3.0
0.99
1.77
mmol/l
0.37
15
68
16
89
1.90
1.44
7.7
6.9
4.94
5.08
kpa
0.19
16
84
16
89
1.90
1.44
7.7
6.8
12.76
13.34
kpa
0.18
16
84
19
293
0.59
1.30
1.2
1.3
1.36
7.53
u/ml
—
7
114
108
1170
0.66
1.16
4.2
4.1
5.75
5.67
mmol/l
0.24
101
1101
9
49
1.89
1.01
32.0
2.3
1.19
1.25
%
—
9
49
140
1371
+∞
0.99
41.7
19.8
135.46
135.34
g/l
0.04
140
1362
0
28
0.00
0.99
0.0
1.4
—
—
—
0
0
140
1370
+∞
0.98
44.4
19.9
40.46
40.61
%
0.14
140
1361
7
36
1.99
0.98
1.3
1.7
69.86
34.25
nmol/l
—
7
36
116
1232
0.66
0.98
4.1
4.4
4.81
4.77
mmol/l
0.18
111
1178
140
1369
+∞
0.97
41.4
19.6
91.69
90.33
fl
3.34
140
1361
116
1229
0.67
0.91
4.0
4.3
1.48
1.50
mmol/l
0.13
110
1172
6
29
2.12
0.90
1.0
1.2
—
—
—
0
0
125
1179
1.56
0.85
6.8
5.6
1.86
1.73
mu/l
0.48
120
1120
0
26
0.00
0.79
0.0
1.8
—
—
—
0
0
8
131
0.59
0.78
1.4
1.3
31.09
21.15
iu/l
—
8
106
13
194
0.64
0.78
1.6
1.6
332.85
456.50
pmol/l
2.62
13
173
37
297
1.33
0.73
2.1
2.0
—
—
—
0
0
18
128
1.47
0.70
1.6
1.2
86.84
143.35
u/ml
—
9
50
5
29
1.75
0.64
1.8
2.2
—
—
—
0
0
40
337
1.26
0.55
1.8
1.6
—
—
—
0
0
44
376
1.25
0.54
2.3
2.5
50.55
57.06
u/l
1.17
44
356
22
277
0.76
0.53
1.6
1.9
—
—
—
0
0
111
1163
0.78
0.51
3.3
3.6
1.14
1.24
mmol/l
1.26
104
1094
108
1020
1.26
0.49
4.5
4.0
—
—
—
0
0
7
46
1.55
0.49
1.3
1.3
—
—
—
0
0
7
49
1.45
0.46
1.6
1.3
—
—
—
0
0
11
78
1.45
0.44
1.7
1.6
—
—
—
0
0
44
384
1.21
0.44
1.4
1.7
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
4.3
—
47.09
—
0
17
0
18
0.00
0.40
0.0
1.1
—
6.56
—
0
9
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
39
341
1.20
0.38
9.4
3.6
0.00
0.00
estimate
-0.00
11
131
22
183
1.24
0.34
2.4
2.0
—
—
—
0
0
6
87
0.68
0.34
1.3
1.4
—
—
—
0
0
56
610
0.86
0.33
2.3
2.6
—
—
estimate
—
0
0
34
298
1.19
0.32
8.7
3.8
9.94
11.63
mg/mmol
0.12
28
179
28
319
0.85
0.29
1.3
1.3
9.60
27.81
iu/ml
—
7
92
9
72
1.27
0.26
1.7
1.4
—
—
—
0
0
121
1238
0.83
0.24
4.6
4.7
2.90
2.84
mmol/l
0.35
114
1183
52
482
1.13
0.23
8.3
3.4
0.00
0.00
estimate
—
10
117
7
94
0.73
0.23
7.0
3.3
—
—
—
0
0
18
209
0.84
0.23
1.5
2.0
3.33
3.42
ratio
0.14
13
162
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
1203.50
—
0
10
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
10
80
1.27
0.21
3.6
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
7
58
1.22
0.18
1.6
1.7
—
—
—
0
0
5
69
0.71
0.17
1.0
1.1
1.76
1.59
g/l
—
5
69
17
149
1.16
0.16
2.3
1.9
—
—
—
0
0
7
86
0.80
0.15
2.7
2.6
30.57
28.75
u/ml
—
7
80
10
84
1.21
0.14
2.5
1.6
609.70
339.04
mu/l
—
10
74
31
288
1.10
0.13
8.5
3.3
1.02
1.02
kg/l
0.14
23
189
38
358
1.08
0.12
1.4
1.3
0.61
1.30
u/ml
—
9
104
39
369
1.08
0.11
5.6
3.0
0.00
0.00
estimate
—
10
111
28
299
0.92
0.10
1.5
2.1
—
—
—
0
0
6
54
1.12
0.09
7.0
3.2
2.85
0.22
mmol/l
—
6
38
5
63
0.79
0.08
1.0
1.7
—
—
—
0
0
15
137
1.11
0.08
2.3
2.0
394.80
385.52
nmol/l
0.05
15
127
6
71
0.84
0.08
1.0
1.2
0.90
0.85
g/l
—
6
71
12
110
1.10
0.05
3.4
4.4
17.70
21.06
%
—
5
46
54
529
1.03
0.03
1.8
1.8
1.36
1.38
mmol/l
0.06
48
472
15
158
0.94
0.02
1.6
1.9
3.42
3.48
mmol/l
—
10
113
12
113
1.07
0.02
7.9
4.8
—
—
—
0
0
38
373
1.03
0.01
3.2
2.9
16.00
18.81
ng/l
0.25
17
193
14
144
0.97
0.00
3.5
4.0
1.31
1.70
ug/l
0.67
14
134
8
82
0.97
0.00
1.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.8
—
248.20
—
0
5
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
9
0.00
-0.00
0.0
1.0
—
158.11
—
0
9
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.34
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
15.17
—
0
6
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
79
1.01
-0.00
1.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
55.14
—
0
9
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
10.66
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
56.20
—
0
5
0
7
0.00
-0.00
0.0
6.1
—
332.14
—
0
7
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
7.60
—
0
5
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
12.70
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint H7_RETROBULBNEURINOTH and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have H7_RETROBULBNEURINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: H7_RETROBULBNEURINOTH – Retrobulbar neuritis in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data